




Korean Cancer Association

Curriculum Vitae	
Full Name	Ahmed Omar Kaseb, MD, CMQ
Affiliation	The University of Texas MD Anderson Cancer Center
Department	Gastrointestinal Medical Oncology
Current Position	Associate Professor
Country	Houston, Texas, USA
	
Education	
Degree-Granting Education Cairo University School of Medicine, Egypt, MBBS, 1996	
Postgraduate Training Clinical Internship, Medicine, Cairo University Hospitals, Cairo, Egypt, 3/1997–2/1998 Externship, Internal Medicine, Michigan State University, Flint, MI, 12/1998–6/1999 Research Fellowship, University of Michigan, Ann Arbor, MI, 9/1999–6/2001 Internal Medicine Residency, Wayne State University, Detroit, MI, 7/2001–6/2004 Internal Medicine Staff Physician, Henry Ford Hospital, Detroit, MI, 7/2004–6/2005 Medical Oncology Fellow, Henry Ford Hospital, Detroit, MI, 7/2005–6/2007	
Board Certification American Board of Internal Medicine American Board of Medical Oncology American Board of Medical Quality	
Professional Experience	
Academic Appointments Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2007–present	
Administrative Appointments/Responsibilities Editor-in-Chief: Journal of Hepatocellular Carcinoma Member: NIH/NCI Liver Cancer/HCC Working Group	

Korean Cancer Association

Room 1824, Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea

Tel: +82-2-792-1486 Fax: +82-2-792-1410 E-mail: cancer2@kams.or.kr Website: www.cancer.or.kr



Korean Cancer Association

Co-Chair: Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline Panel, American Society of Clinical oncology

Chair, Steering Committee: Hepatocellular Carcinoma International Biomarkers Assessment Consortium (HIBAC): with MD Anderson Cancer Center sister institutions network, Korea, Thailand, Turkey, Egypt, and China.

Member, Executive Committee, Harris County Medical Society: Houston, Texas: 2017-2018

Chair, Council of International and Affiliated Medical Societies: Harris County Medical Society, Houston, Texas: 2017/2018

Member: Clinical Research Committee, The University of Texas MD Anderson Cancer Center, Houston, TX

Member: Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, Houston, TX: 2013-2016

Funded Research Trials (Principal Investigator):

An Open-Label Preoperative Pilot Study Evaluating Nivolumab Alone Versus Nivolumab Plus Ipilimumab in Patients with Resectable and Potentially Resectable HCC (CA209-956) (2016-2020)

A Phase I/II to Investigate the Safety, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (Pembrolizumab) in Advanced HCC in subjects who progressed or were intolerant to sorafenib. (2016-2018)

A Phase I/II study of pembrolizumab plus Zepatier in Advanced HCC in subjects with hepatitis C who progressed or were intolerant to sorafenib. (2018-2020)

A Phase I/II study of pembrolizumab plus lenvatinib in Advanced HCC. (2018-2020)

Phase I trial evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with HCC (ACTengine IMA202-101) (2018-2020)

A Phase II study of Sorafenib + Yttrium-90 for Advanced HCC, BCLC Stage C. (2013-2018)

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic HCC (2018-2020)

A Phase 1 Trial of ABT-263 (Navitoclax), a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors. (NCI9608) (201-2020)

Korean Cancer Association

Room 1824, Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea

Tel: +82-2-792-1486 Fax: +82-2-792-1410 E-mail: cancer2@kams.or.kr Website: www.cancer.or.kr